^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    FANCG (FA Complementation Group G)

    i
    Other names: FANCG, FA Complementation Group G, DNA Repair Protein XRCC9, X-Ray Repair Complementing Defective Repair In Chinese Hamster Cells 9, X-Ray Repair, Complementing Defective, In Chinese Hamster, 9, Fanconi Anemia Complementation Group G, Fanconi Anemia Group G Protein, XRCC9, Truncated Fanconi Anemia Group G Protein, Protein FACG, FAG
    14d
    Whole Exome Sequencing Revealed Rare Variants in BRCA2, RAD51D, FANGC, CYP24A1 Genes in Breast/Ovarian Cancer Patients from a Small Buryat Ethnic Group. (PubMed, Asian Pac J Cancer Prev)
    For the first time, rare germinal variants in the BRCA2, RAD51D, FANGC, CYP24A1 genes were detected in a small Buryat ethnic group. Our data are consistent with existing data showing that variants in the RAD51D gene may be involved in the pathogenesis of breast/ovarian cancer. We also showed that the Mongolic-speaking Buryat populations exhibited strong genetic resemblance to those of Chinese.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51D (RAD51 paralog D) • FANCG (FA Complementation Group G) • FOXL2 (Forkhead Box L2)
    1m
    NCI-2017-02296: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (clinicaltrials.gov)
    P2, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • ABL1 (ABL proto-oncogene 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • POLE (DNA Polymerase Epsilon) • CCND1 (Cyclin D1) • BAP1 (BRCA1 Associated Protein 1) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • POLD1 (DNA Polymerase Delta 1) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • FANCL (FA Complementation Group L) • BRD4 (Bromodomain Containing 4) • DOT1L (DOT1 Like Histone Lysine Methyltransferase) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • IKBKE (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Epsilon) • FANCC (FA Complementation Group C)
    |
    PALB2 mutation • BRIP1 mutation
    |
    FoundationOne® CDx • FoundationOne® Liquid CDx
    |
    Lynparza (olaparib)
    4ms
    Comparison of Familial and Sporadic Pancreatic Cancer: Clinicopathological and Genomic Features. (PubMed, Ann Surg Oncol)
    Transcriptomic profiles and HRD status were similar between patients with FPC and patients with non-FPC. A spectrum of GLMs was observed in both groups, suggesting that hereditary risk variants are not exclusive to FPC and underscoring the importance of germline testing in all patients with PC.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • FANCG (FA Complementation Group G) • SPINK1 (Serine peptidase inhibitor, kazal type 1)
    |
    HRD
    5ms
    Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry. (PubMed, Nat Commun)
    Besides notable impact of DNA polymerases, including POLG, Fanconi anaemia genes include FANCD2, FANCA, FANCG, ERCC4, FANCE and FANCI, while DNA mismatch repair genes MSH3 and PMS1 outranked known namesakes MSH6 and PMS2. This study provides insights into the spectrum of African-relevant potentially pathogenic PCa variants, highlighting much-needed gene candidates for ancestry-inclusive germline testing.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MLH1 (MutL homolog 1) • LRP1B (LDL Receptor Related Protein 1B) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • CDK12 (Cyclin dependent kinase 12) • PMS2 (PMS1 protein homolog 2) • FAT1 (FAT atypical cadherin 1) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • MSH3 (MutS Homolog 3) • PREX2 (Phosphatidylinositol-3,4,5-Trisphosphate Dependent Rac Exchange Factor 2) • PMS1 (PMS1 protein homolog 1) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • FANCI (FA Complementation Group I) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • HOXB13 (Homeobox B13)
    6ms
    Potential role of Fanconi anemia pathway in the pathogenesis of endometrial cancer (Review). (PubMed, Mol Med Rep)
    This comprehensive review provides a systematic summary of EC‑related FA genes, elucidates the roles of various FA genes in EC and further speculates on their related mechanisms to facilitate the development of targeted therapies that specifically target key genes, leading to a more accurate and efficient treatment for EC. The present review searched PubMed and Google Scholar for articles published in English up to June 2025 using keywords such as Fanconi anemia pathway, 22 FA genes (FANCA, FANCB, FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ/BRIP1, FANCL, FANCM, FANCN/PALB2, FANCO/RAD51C, FANCP/SLX4, FANCQ/XPF, FANCR/RAD51, FANCS/BRCA1, FANCT/UBE2T, FANCU/XRCC2, FANCV/REV7, FANCW/RFWD3), endometrial cancer (type I: Endometrioid adenocarcinoma; Type II Uterine serous carcinoma, clear‑cell carcinoma, carcinosarcoma), somatic copy number alterations, microsatellite instability, TP53 mutations, pathogenesis, genomic instability, target therapy.
    Review • Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • PALB2 (Partner and localizer of BRCA2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • FANCF (FA complementation group F) • FANCL (FA Complementation Group L) • XRCC2 (X-Ray Repair Cross Complementing 2) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • FANCI (FA Complementation Group I) • FANCM (FA Complementation Group M) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCG (FA Complementation Group G) • FANCB (FA Complementation Group B) • FANCC (FA Complementation Group C) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    TP53 mutation
    7ms
    Single-nucleotide polymorphisms in DNA repair genes ERCC, XRCC, and MGMT and implications in glioblastoma: a pathway analysis and structural dynamics study. (PubMed, J Biomol Struct Dyn)
    The present investigation indicated the significance of GBM-associated DDR gene SNVs in protein dynamics and GBM pathogenesis. This study suggests notable changes in the biophysical structural parameters of mutated ERCC2 and XRCC3, whereas changes in certain parameters of mutant XRCC2/MGMT were less prominent.
    Journal
    |
    ERCC2 (Excision repair cross-complementation group 2) • XRCC2 (X-Ray Repair Cross Complementing 2) • FANCG (FA Complementation Group G) • XRCC3 (X-Ray Repair Cross Complementing 3)
    7ms
    MK3475-A53: Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting | N=26 --> 9 | Trial primary completion date: Dec 2025 --> Feb 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • HRD (Homologous Recombination Deficiency) • BAP1 (BRCA1 Associated Protein 1) • KMT2D (Lysine Methyltransferase 2D) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • WRN (WRN RecQ Like Helicase) • FANCG (FA Complementation Group G) • ABRAXAS1 (Abraxas 1 BRCA1 A Complex Subunit 2) • SLX4 (SLX4 Structure-Specific Endonuclease Subunit)
    |
    HRD
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    8ms
    Identification of FANCG as a prognostic factor for prostate cancer. (PubMed, Eur J Med Res)
    This study suggests that FANCG likely plays a pivotal role in PCa progression. In addition, increased FANCG expression may serve as an indicator of poor disease-free survival and an adverse prognosis for PCa patients.
    Journal
    |
    POLD1 (DNA Polymerase Delta 1) • FANCG (FA Complementation Group G) • LRIG1 (Leucine Rich Repeats And Immunoglobulin Like Domains 1) • MCM5 (Minichromosome Maintenance Complex Component 5) • MCM7 (Minichromosome Maintenance Complex Component 7) • POLA2 (DNA Polymerase Alpha 2)
    9ms
    Sequence Variation in X-ray Cross Complimenting (XRCC4, XRCC5, XRCC6 and XRCC7) Genes and the Risk of Gastrointestinal Cancer in South-Western Maharashtra: A Hospital Based Case-Control Study. (PubMed, Asian Pac J Cancer Prev)
     However, we did not find any association of polymorphic variants of XRCC4.1 cd247, XRCC4.5 Intron-7 and XRCC6 61C>G with GI cancer risk in the study population. However, multicentric studies with larger sample size are needed to substantiate the findings.
    Journal
    |
    FANCG (FA Complementation Group G) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit)
    11ms
    Clinicopathologic and molecular characterization of primitive neuroectodermal tumors (PNET) in the female genital tract: a retrospective study of 8 cases. (PubMed, Hum Pathol)
    Our findings confirm that cervical/vaginal and ovarian PNET represent two distinct tumor types. Ovarian PNET have different pathogenetic pathways from their CNS and testicular counterparts most likely.
    Retrospective data • Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • EWSR1 (EWS RNA Binding Protein 1) • INPP4B (Inositol polyphosphate-4-phosphatase type II B) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule) • FANCG (FA Complementation Group G)
    11ms
    The combination of poly(ADP-ribose) polymerase inhibitor and statin inhibits the proliferation of human castration-resistant and taxane-resistant prostate cancer cells in vitro and in vivo. (PubMed, BMC Cancer)
    Simvastatin altered the expression of several genes associated with DNA repair in castration-resistant and taxane-resistant prostate cancer cells. The combination of poly (ADP-ribose) polymerase inhibitors and drugs that decrease DNA repair gene expression can potentially affect castration-resistant and taxane-resistant prostate cancer growth.
    Preclinical • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BARD1 (BRCA1 Associated RING Domain 1) • FANCD2 (FA Complementation Group D2) • FANCG (FA Complementation Group G) • RFC4 (Replication Factor C Subunit 4)
    |
    Lynparza (olaparib) • cabazitaxel • simvastatin
    12ms
    Novel De Novo BRCA2 Variant in an Early-Onset Ovarian Cancer Reveals a Unique Tumor Evolution Pathway. (PubMed, Int J Mol Sci)
    Furthermore, ECM components, such as collagen isoforms, Fibrillin-1, EMILIN-1, Prolargin, and Lumican, were found to be highly expressed in the MLH1/PMS2-deficient tumor area, suggesting a connection between DNA repair deficiencies, ECM remodeling, and tumor progression. Thus, the identification of the BRCA2 variant sheds light on the poorly understood interplay between DNA repair deficiencies and ECM remodeling in OC, providing new insights into their dual role in shaping tumor evolution and suggesting potential targets for novel therapeutic strategies.
    Journal • BRCA Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • BCL6 (B-cell CLL/lymphoma 6) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2) • NOTCH2 (Notch 2) • KDM6A (Lysine Demethylase 6A) • CUX1 (cut like homeobox 1) • DRD (DNA Repair Deficiency) • FANCG (FA Complementation Group G) • LUM (Lumican)